The National Institute for Health and Care Excellence (NICE) has released a positive final appraisal determination for Novartis’ Cosentyx (secukinumab) for use in adults with active and progressive psoriatic arthritis.

NICE is recommending use of Cosentyx when a patient has peripheral arthritis with three or more tender joints and three or more swollen joints and has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs, administered either individually or in combination.

The drug is a biologic therapy that selectively binds to IL17A and stops it from binding to its receptors and prevents inflammation.